1 Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007;48(4):573–85.
doi:10.3349/ymj.2007.48.4.573.
2 de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.
doi:10.1002/art.24642.
3 Zouboulis CC, Büttner P, Djawari D, et al. [The HLA pattern in Adamantiades-Behçet’s disease in Germany. Association of occurrence, clinical symptoms and follow-up in 39 patients]. Hautarzt. 1993;44(2):81–5.
4 Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions. J Dermatol. 2016;43(6):620–32.
doi:10.1111/1346-8138.13381.
5 Criteria for diagnosis of Behçet«s disease. International Study Group for Behçet’s Disease. Lancet. 1990;335(8697):1078–80.
6 Alpsoy E, Uzun S, Akman A, Acar MA, Memişoglu HR, Başaran E. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Behçet’s disease. J Eur Acad Dermatol Venereol. 2003;17(5):521–4.
7 Altenburg A, Papoutsis N, Orawa H, Martus P, Krause L, Zouboulis CC. [Epidemiology and clinical manifestations of Adamantiades-Behçet disease in Germany – current pathogenetic concepts and therapeutic possibilities]. J Dtsch Dermatol Ges. 2006;4(1):49–64, quiz65–6.
doi:10.1111/j.1610-0387.2006.05841.x.